Celyad Oncology SA
Company Profile
Business description
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
Contact
Rue Edouard Belin 2
Axis Business Park
Brabant Wallon
Mont-Saint-Guibert1435
BELT: +32 10394100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
39
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,639.30 | 1.50 | 0.02% |
| CAC 40 | 7,779.72 | 8.38 | -0.11% |
| DAX 40 | 23,933.23 | 104.96 | -0.44% |
| Dow JONES (US) | 42,215.73 | 117.03 | 0.28% |
| FTSE 100 | 8,716.45 | 9.56 | -0.11% |
| HKSE | 23,220.87 | 352.51 | -1.50% |
| NASDAQ | 19,175.87 | 74.93 | 0.39% |
| Nikkei 225 | 37,917.38 | 515.60 | -1.34% |
| NZX 50 Index | 12,378.17 | 96.86 | 0.79% |
| S&P 500 | 5,912.17 | 23.62 | 0.40% |
| S&P/ASX 200 | 8,413.90 | 4.10 | 0.05% |
| SSE Composite Index | 3,344.72 | 18.72 | -0.56% |